TP53 and B-cell chronic lymphocytic leukemia: The GAIA trial compared three different fixed-duration venetoclax-based combinations (obinutuzumab + venetoclax, O + V; obinutuzumab + ibrutinib + venetoclax, O + I + V; rituximab + venetoclax, R + V) against chemoimmunotherapy (CIT) in fit, treatment-naïve CLL patients (n = 926) without 17p deletion or TP53 mutation.